1. Home
  2. RPC vs VALN Comparison

RPC vs VALN Comparison

Compare RPC & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ridgepost Capital Inc. Class A Common Stock

RPC

Ridgepost Capital Inc. Class A Common Stock

N/A

Current Price

$7.63

Market Cap

932.7M

Sector

Finance

ML Signal

N/A

Logo Valneva SE

VALN

Valneva SE

N/A

Current Price

$10.51

Market Cap

875.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
RPC
VALN
Founded
1992
2012
Country
United States
France
Employees
267
N/A
Industry
Investment Managers
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
932.7M
875.7M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
RPC
VALN
Price
$7.63
$10.51
Analyst Decision
Buy
Strong Buy
Analyst Count
1
4
Target Price
$11.00
$15.75
AVG Volume (30 Days)
744.1K
17.1K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
1.95%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$18.96
$2.58
Revenue Next Year
$13.18
$4.43
P/E Ratio
$53.06
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.51
$5.43
52 Week High
$9.32
$12.25

Technical Indicators

Market Signals
Indicator
RPC
VALN
Relative Strength Index (RSI) 31.61 53.01
Support Level $7.63 $8.37
Resistance Level N/A $12.22
Average True Range (ATR) 0.36 0.40
MACD -0.07 -0.07
Stochastic Oscillator 8.79 35.11

Price Performance

Historical Comparison
RPC
VALN

About RPC Ridgepost Capital Inc. Class A Common Stock

Ridgepost Capital Inc, formelrly P10 Inc is a player in the alternative asset management sector, specializing in multi-asset class private market solutions. It offers a range of investment solutions, including specialized funds, separate accounts, secondary investments, direct investments, and co-investments across various asset classes and geographies. These solutions cater to diverse investor needs within the private markets, aiming to deliver superior risk-adjusted returns. With a focus on middle and lower-middle markets, the company's portfolio includes Private Equity, Venture Capital, Impact Investing, and Private Credit. Its Revenue primarily comes from recurring management and advisory fees earned on committed capital, typically locked up for ten to fifteen years.

About VALN Valneva SE

Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.

Share on Social Networks: